EDUCATION
November 30, 2022 Specialization in Clinical Pathology and Clinical Biochemistry, Sapienza University of Rome.
July 6, 2010 PhD in Epidemiology and Molecular Pathology, Department of Experimental Medicine, Sapienza University of Rome.
October 26, 2006 Master’s Degree (Laurea Magistrale) in Genetics and Molecular Biology, Sapienza University of Rome (summa cum laude, 110/110).
ACADEMIC AND PROFESSIONAL APPOINTMENTS
December 15, 2023 – Present
Tenure-Track Researcher (RTT), SSD MED/26a (formerly MED/46), Department of Experimental Medicine, Sapienza University of Rome.
March 1, 2022 – December 14, 2023
Research Fellow (Cat. A – Type II – SSD MED/04), Department of Experimental Medicine, Sapienza University of Rome.
Project: Identification of biological mechanisms underlying hormone-sensitive neoplasms in in vivo models.
2018 – 2022
Resident Physician in Clinical Pathology and Clinical Biochemistry, Sapienza University of Rome.
Thesis: Diagnostic dilemmas in patients with sepsis caused by multidrug-resistant Enterobacterales.
Conducted at the Microbiology and Virology Unit, Policlinico Umberto I Hospital, Rome.
May 2 – December 31, 2022
Research Fellow, Istituto Neurologico Mediterraneo Neuromed IRCCS.
Molecular Pathology Unit – Research activities within the framework of Current Research 2022 projects in neuroscience.
January 31, 2022
National Scientific Qualification (ASN) for Associate Professor (Seconda Fascia), Competition Sector 06/N1 – Health Professions and Applied Medical Technologies.
March 1, 2020 – February 28, 2022
Research Fellow (Cat. A – Type II – SSD MED/46), Department of Experimental Medicine, Sapienza University of Rome.
Project: Role of KCASH2–MAD2 interaction in the regulation of the mitotic checkpoint, aneuploidy, and tumorigenesis.
March 1, 2019 – February 29, 2020
Research Fellow (Cat. B – Type II – SSD MED/04), Department of Experimental Medicine, Sapienza University of Rome.
Project: Characterization of circulating microRNAs as early and sensitive biomarkers of metabolic alterations in obesity and development of novel diagnostic platforms for chronic metabolic diseases.
January 2, 2014 – December 31, 2018
Fixed-Term Researcher (RTD-A), Department of Molecular Medicine, Sapienza University of Rome.
Research lines:
• Molecular bases of disease: microRNA-mediated gene regulation mechanisms.
• Stem cells in development and disease: Hedgehog signaling in neuronal development and pathology.
Scientific activity focused on the characterization of bioactive molecules and their biological effects in vitro (2D and 3D cell cultures) and in vivo using animal models of metabolic, inflammatory, and oncological diseases.
February 1, 2013 – December 31, 2013
Research Fellow (Cat. B – Type II – SSD MED/04), Department of Molecular Medicine, Sapienza University of Rome.
Project: Role of translational control in Hedgehog-regulated neural differentiation.
June 1, 2012 – December 31, 2012
Research Associate, Department of Medicine, Section of Inflammation and Signal Transduction, Division of Immunology, Imperial College London, UK.
June 1, 2010 – May 31, 2012
Visiting Researcher, Department of Medicine, Section of Inflammation and Signal Transduction, Division of Immunology, Imperial College London, UK.
Awarded competitive international fellowship from Istituto Pasteur – Fondazione Cenci Bolognetti.
February 1, 2010 – May 30, 2010
Research Fellow (SSD MED/04), Department of Experimental Medicine, Sapienza University of Rome.
Project: Molecular relationships between MYCN-induced DNA damage response and mechanisms of resistance/sensitivity to clastogenic agents in neuroblastoma carcinogenesis.
2006 – 2009
PhD Candidate, Doctoral School in Epidemiology and Molecular Pathology, Department of Experimental Medicine, Sapienza University of Rome.
November 2006
Licensed Biologist. Registered with the Italian National Order of Biologists (Registration No. AA_087046).
PROFESSIONAL AND ACADEMIC SERVICE
• Member, Scientific Research Committee (Macroarea B), Sapienza University of Rome (2025–present).
• Member, PhD Board in Network Oncology and Precision Medicine (2024–present).
• Member, Departmental Scientific Committee for PRIN 2022 and PRIN 2022 PNRR (2024–present).
• Member, Quality Assurance Committee, MD Program (Rieti campus) (2024–2025).
• Chair of Admission Examination Committees for Health Professions and Medicine and Surgery degree programs (2024).
TEACHING AND MENTORING ACTIVITY
Since 2013, continuous teaching and tutoring activities within undergraduate (MD program, Biomedical Laboratory Techniques, Physiotherapy, Speech Therapy, Nursing), PhD programs (Molecular Medicine; Network Oncology and Precision Medicine), and elective internships in Molecular Pathology.
Courses taught include:
• Laboratory Medicine Sciences (MED/46)
• Cellular and Molecular Bases of Life (MED/07)
• Pathophysiological Bases of Disease (MED/04, MED/05)
• Molecular Diagnostic Technologies and Molecular Oncology
Regular member of examination committees for General Pathology and Pathophysiology (17 CFU), MD Program.
RESEARCH ACTIVITY
Dr Marta Moretti’s research focuses on the molecular biology of cancer, with a particular interest in Hedgehog (Hh) and NF κB signaling pathways in medulloblastoma, colorectal cancer, and other solid and hematologic malignancies. She has made substantial contributions to the characterization of cerebellar Hh pathway modulators (the KCASH family) and related KCTD members (KCTD15, KCTD1), elucidating their role in controlling HDAC1, Hh/Gli1 activity, and the proliferation of Hh dependent tumor cells, and identifying new potential therapeutic targets. In parallel, she has been involved in numerous collaborative studies using models of endocrine metabolic diseases, acute and chronic inflammatory conditions, and solid tumors, contributing to the discovery of novel biomarkers and drug targets through the analysis of bioactive molecules in vitro and in vivo.
From a methodological standpoint, she has extensive expertise in 2D and 3D cell culture systems (including primary cerebellar cultures, MEFs, and neurospheres), genetic editing using CRISPR Cas9, and the use of viral vectors (adenoviral/lentiviral) for gene overexpression or silencing (shRNA, siRNA, miRNA, antago miR), as well as in murine models of metabolic, inflammatory, and oncologic diseases to evaluate innovative therapeutic strategies. In recent years, she has significantly expanded her work to pancreatic cancer, focusing on molecular and circulating biomarkers in pancreatic ductal adenocarcinoma and on EMT related markers such as PIVKA II and vimentin, and to hematologic malignancies, contributing to studies on drug resistance in ALK+ lymphomas and on proteasome dependent degradation mechanisms of the oncogenic transcription factor GLI1.
RESEARCH FUNDING
Principal Investigator (PI):
• 2024–present: University Research Project (Progetti di Ateneo Medi): A new model of IBD-related colorectal cancer: role of the Hedgehog pathway and its molecular characterization.
• 2023–2024: University Start-up Grant (Type 2): In vivo characterization of KCASH2 in colorectal tumorigenesis.
• 2022–2023: University Start-up Grant (Type 2): CRISPR-Cas9–generated cellular models to study KCASH2 in tumorigenesis.
• 2021–2022: University Start-up Grant (Type 2): KCASH2–MAD2 interaction in mitotic checkpoint regulation.
• 2014–2015: University Start-up Grant (Type 2): Role of KCASH2 in mitotic checkpoint regulation and chromosomal instability-associated tumorigenesis.
Participant in multiple national competitive grants including PRIN 2022, PRIN-PNRR 2022, and AIRC-funded projects (2013, 2017).
SCIENTIFIC MEETINGS
• Scientific Committee Member, 36th AICC International Meeting 2024.
• Scientific Committee Member, III International AICC Exosome Meeting (2021).
• Invited Speaker, AICC Annual Conference (2019).
• Invited Speaker, Imperial College London “Away Day” (2012).
AWARDS
• 2019 SIPMeT Award “Prof. Alberto Gulino” for young investigators in experimental oncology.
• 2011 International Research Fellowship, Istituto Pasteur – Fondazione Cenci Bolognetti.
• 2010 International Research Fellowship, Istituto Pasteur – Fondazione Cenci Bolognetti.
MANDATORY LEAVE PERIODS
• February 18, 2014 – July 18, 2014
• September 17, 2015 – February 17, 2016
Scientific production
Total number of publications in international peer-reviewed journals: 35
Book chapters: 2
H-index: 19 (Scopus)
Total Impact factor (JCR): 222,43
Average Impact factor (JCR): 6.355
Total Citations: 1694(Scopus)
Average Citations per Product: 45,78
1. Pignataro C, Zoppoli P, Cappelli LV, Yoffe L, Moretti M, Izzo M, Mallia S, Kayembe C, Taylor A, Petrillo G, Affinito A, Quintavalle C, De Luca G, Mascolo M, Verde S, Fraticelli A, Ciarrocchi A, Salerno P, De Smaele E, Campese AF, Fragliasso V, Foà R, Merla G, Inghirami GG, Condorelli G, Fiore D. BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. Blood Adv. 2025 Jul 2:bloodadvances.2024015322. doi: 10.1182/bloodadvances.2024015322. Epub ahead of print. PMID: 40601898. IF 7.1
2. Bordin F, Terriaca G, Apostolico A, Di Fiore A, Mir FT, Bellardinelli S, Bufalieri F, Bordone R, Bellardinilli F, Giannini G, Canettieri G, Di Marcotullio L, Ferretti E, Moretti M and De Smaele E. SMURF1 and SMURF2 directly target GLI1 for ubiquitination and proteasome-dependent degradation. Cell Death Discov. 2024 Dec 18;10(1):498. doi:10.1038/s41420-024-02260-4. PMID: 39695131; PMCID: PMC11655642. IF 6.1 (Co-Last name)
3. Moretti M., Farina A., Angeloni A., Anastasi E. Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma. Front Oncol. 2024 Nov 7;14:1483306. doi: 10.3389/fonc.2024.1483306. PMID: 39575418; PMCID: PMC11578827. IF 3.5
4. Farina A., Viggiani V., Cortese F., Moretti M., Tartaglione S., Angeloni A., Anastasi E. Combined PIVKA II and Vimentin-Guided EMT Tracking in Pancreatic Adenocarcinoma. Cancers 2024, 16, 2362. https://doi.org/10.3390/cancers16132362 IF 4.5
5. Lospinoso Severini L, Loricchio E, Navacci S, Basili I, Alfonsi R, Bernardi F, Moretti M, Conenna M, Cucinotta A, Coni S, Petroni M, De Smaele E, Giannini G, Maroder M, Canettieri G, Mastronuzzi A, Guardavaccaro D, Ayrault O, Infante P, Bufalieri F, Di Marcotullio L. SALL4 is a CRL3REN/KCTD11 substrate that drives Sonic Hedgehog-dependent medulloblastoma. Cell Death Differ. 2023 Dec 7. doi: 10.1038/s41418-023-01246-6. Epub ahead of print. PMID: 38062245. IF 12.4
6. Molfetta R, Lecce M, Milito ND, Putro E, Pietropaolo G, Marangio C, Scarno G, Moretti M, De Smaele E, Santini T, Bernardini G, Sciumè G, Santoni A, Paolini R. SCF and IL-33 regulate mouse mast cell phenotypic and functional plasticity supporting a pro-inflammatory microenvironment. Cell Death Dis. 2023 Sep 20;14(9):616. doi: 10.1038/s41419-023-06139-7. PMID: 37730723; PMCID: PMC10511458. IF 9.696
7. Di Fiore A, Bellardinelli S, Pirone L, Russo R, Angrisani A, Terriaca G, Bowen M, Bordin F, Besharat ZM, Canettieri G, Fabretti F, Di Gaetano S, Di Marcotullio L, Pedone E, Moretti M#, De Smaele E. KCTD1 is a new modulator of the KCASH family of Hedgehog suppressors. Neoplasia. 2023 Sep;43:100926. doi: 10.1016/j.neo.2023.100926 IF 4.8 (#Co-ultimo nome)
8. Abballe L, Alfano V, Antonacci C, Cefalo MG, Cacchione A, Del Baldo G, Pezzullo M, Po A, Moretti M, Mastronuzzi A, De Smaele E, Ferretti E, Locatelli F and Miele E. β-arrestin1-E2F1-ac axis regulates physiological apoptosis and cell cycle exit in cellular models of early postnatal cerebellum Front. Cell Dev. Biol., 27 Feb 2023; Volume 11 – 2023 doi.org/10.3389/fcell.2023.990711 IF 6.081
9. Petroni M, Fabretti F, Di Giulio S, Nicolis di Robilant V, La Monica V, Moretti M, Belardinilli F, Bufalieri F, Coppa A, Paci P, Corsi A, De Smaele E, Coni S, Canettieri G, Di Marcotullio L, Wang ZQ, Giannini G. A gene dosage-dependent effect unveils NBS1 as both a haploinsufficient tumour suppressor and an essential gene for SHH-medulloblastoma. Neuropathol Appl Neurobiol. 2022 Oct;48(6):e12837. doi: 10.1111/nan.12837. IF 8.09
10. Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, Angiolini V, Ciuffa S, Cifaldi L, Carrano R, Palumbo C, Miele MT, Bei R, Barillari G, Manzari V, De Smaele E, Modesti A, Masuelli L. Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo. J Transl Med. 2022 Jun 25;20(1):286. doi: 10.1186/s12967-022-03490-9. PMID: 35752861; PMCID: PMC9233819. IF 4.965
11. Overi D, Carpino G, Moretti M, Franchitto A, Nevi L, Onori P, De Smaele E, Federici L, Santorelli D, Maroder M, Reid LM, Cardinale V, Alvaro D, Gaudio E. Islet Regeneration and Pancreatic Duct Glands in Human and Experimental Diabetes. Front Cell Dev Biol. 2022 Feb 4;10:814165. doi: 10.3389/fcell.2022.814165. PMID: 35186929; PMCID: PMC8855925. IF 6.684
12. Di Giulio S, Colicchia V, Pastorino F, Pedretti F, Fabretti F, Nicolis di Robilant V, Ramponi V, Scafetta G, Moretti M, Licursi V, Belardinilli F, Peruzzi G, Infante P, Goffredo BM, Coppa A, Canettieri G, Bartolazzi A, Ponzoni M, Giannini G, Petroni M. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. Oncogene. 2021 Sep 10. doi: 10.1038/s41388-021-02003-0. Epub ahead of print. PMID: 34508175. IF 9.867
13. Angrisani A, Di Fiore A, De Smaele E, Moretti M. The emerging role of the KCTD proteins in cancer. Cell Commun Signal. 2021 May 17;19(1):56. doi: 10.1186/s12964-021-00737-8. PMID: 34001146. IF 5.712
14. Di Murro B, Moretti M, De Smaele E, Letizia C, Lubrano C, Passarelli PC, D'Addona A, Pompa G, Papi P. Microbiological Profiles of Dental Implants in Metabolic Syndrome Patients: A Case-Control Study. Antibiotics (Basel). 2021 Apr 16;10(4):452. doi:10.3390/antibiotics10040452. PMID: 33923666; PMCID: PMC8072842. IF 4.639
15. Angrisani A, Di Fiore A, Di Trani CA, Fonte S, Petroni M, Lospinoso Severini L, Bordin F, Belloni L, Ferretti E, Canettieri G, Moretti M#, De Smaele E#. Specific Protein 1 and p53 Interplay Modulates the Expression of the KCTD-Containing Cullin3 Adaptor Suppressor of Hedgehog 2. Front Cell Dev Biol. 2021 Apr 8;9:638508. doi: 10.3389/fcell.2021.638508. PMID: 33898425; PMCID: PMC8060498. IF 6.684 (#Co-ultimo nome)
16. De Blasio C, Verma N, Moretti M, Cialfi S, Zonfrilli A, Franchitto M, Truglio F, De Smaele E, Ichijo H, Naguro I, Screpanti I, Talora C. Functional cooperation between ASK1 and p21Waf1/Cip1 in the balance of cell-cycle arrest, cell death and tumorigenesis of stressed keratinocytes. Cell Death Discov. 2021 Apr 12;7(1):75. doi: 10.1038/s41420-021-00459-3. PMID: 33846306; PMCID: PMC8042117. IF 5.241
17. Infante P, Malfanti A, Quaglio D, Balducci S, De Martin S, Bufalieri F, Mastrotto F, Basili I, Garofalo M, Lospinoso Severini L, Mori M, Manni I, Moretti M, Nicoletti C, Piaggio G, Caliceti P, Botta B, Ghirga F, Salmaso S, Di Marcotullio L. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma. Cancer Lett. 2021 Feb 28;499:220-231. doi: 10.1016/j.canlet.2020.11.028. Epub 2020 Nov 26. PMID: 33249196. IF 8.679
18. Coni S, Serrao SM, Yurtsever ZN, Di Magno L, Bordone R, Bertani C, Licursi V, Ianniello Z, Infante P, Moretti M, Petroni M, Guerrieri F, Fatica A, Macone A, De Smaele E, Di Marcotullio L, Giannini G, Maroder M, Agostinelli E, Canettieri G. Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation. Cell Death Dis. 2020 Dec 10;11(12):1045. doi: 10.1038/s41419-020-03174-6. PMID: 33303756; PMCID: PMC7729396. IF 8.469
19. Po A, Citarella A, Catanzaro G, Besharat ZM, Trocchianesi S, Gianno F, Sabato C, Moretti M, De Smaele E, Vacca A, Fiori ME, Ferretti E (2020). Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells. SCIENTIFIC REPORTS, vol. 10, ISSN: 2045-2322, doi: 10.1038/s41598-020-70871-9. IF 4.379
20. Di Magno L, Manni S, Di Pastena F, Coni S, Macone A, Cairoli S, Sambucci M, Infante P, Moretti M, Petroni M, Nicoletti C, Capalbo C, De Smaele E, Di Marcotullio L, Giannini G, Battistini L, Goffredo BM, Iorio E, Agostinelli E, Maroder M, Canettieri G. Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module. Cell Rep. 2020;30(6):1735-1752. IF 9.423
21. Petroni M, Sahùn Roncero M, Ramponi V, Fabretti F, Nicolis Di Robilant V, Moretti M, Alfano V, Corsi A, De Panfilis S, Giubettini M, Di Giulio S, Capalbo C, Belardinilli F, Coppa A, Sardina F, Colicchia V, Pedretti F, Infante P, Cardinali B, Tessitore A, Canettieri G, De Smaele E, Giannini G. SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors. Sci Rep. 2019 Dec 23;9(1):19623. IF 3.998
22. Spiombi E*, Angrisani A*, Fonte S, De Feudis G,Fabretti F, Cucchi D, Izzo M,Infante P, Miele E, Po A, Di Magno L, Magliozzi R, Guardavaccaro D, Maroder M, Canettieri G, Giannini G, Ferretti E, Gulino A, Di Marcotullio L, Moretti M# & De Smaele E#. KCTD15 inhibits the Hedgehog pathway in Medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2. Oncogenesis 8, 64 (2019). IF 6.119 (#Co-ultimo nome)
23. Lospinoso Severini L, Quaglio D, Basili I, Ghirga F, Bufalieri F, Caimano M, Balducci S, Moretti M, Romeo I, Loricchio E, Maroder M, Botta B, Mori M, Infante P, Di Marcotullio L. A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth. Cancers (Basel). 2019 Oct 9;11(10). IF 6.162
24. Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Lospinoso Severini L, Talbot J, Melaiu O, Tanori M, Di Magno L, Bellavia D, Capalbo C, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Fruci D, Di Marcotullio L. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP. Nat Commun. 2019 Jul 24;10(1):3304. IF 12.121
25. Abballe L, Mastronuzzi A, Miele E, Carai A, Besharat ZM, Moretti M, De Smaele E, Giangaspero F, Locatelli F, Ferretti E, Po A. Numb Isoforms Deregulation in Medulloblastoma and Role of p66 Isoform in Cancer and Neural Stem Cells. Front Pediatr. 2018 Nov 1;6:315. IF 2.349
26. Besharat ZM, Abballe L, Cicconardi F, Bhutkar A, Grassi L, Le Pera L, Moretti M, Chinappi M, D'Andrea D, Mastronuzzi A, Ianari A, Vacca A, De Smaele E, Locatelli F, Po A, Miele E, Ferretti E. Foxm1 controls a pro-stemness microRNA network in neural stem cells. Sci Rep. 2018 Feb 23;8(1):3523. IF 4.011
27. Moretti C, Lanzolla G, Moretti M, Gnessi L, Carmina E. Androgens and Hypertension in Men and Women: a Unifying View. Curr Hypertens Rep. 2017 May;19(5):44. IF 3.234
28. Tornatore L, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 2012 Nov;22(11):557-66. doi: 10.1016/j.tcb.2012.08.001. Epub 2012 Sep 18. IF 11.721
29. Moretti M, Bennett J, Tornatore L, Thotakura AK, Franzoso G. Cancer: NF-κB regulates energy metabolism. Int J Biochem Cell Biol. 2012 Dec;44(12):2238-43. doi: 10.1016/j.biocel.2012.08.002. Epub 2012 Aug 10. IF 4.152
30. Grieco FA, Moretti M, Sebastiani G, Galleri L, Spagnuolo I, Scafetta G, Gulino A, De Smaele E, Maroder M, Dotta F. Delta-cell specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. Diabetes Metabolism Research & Review 2011 Nov;27(8): 755-60. doi: 10.1002/dmrr.1247. IF 3.373
31. Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, Beg A A, Tergaonkar V, Chandel NS, Franzoso G. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nature Cell Biology 2011 Aug;13(10):1272-9 doi: 10.1038/ncb2324. IF 19.488
32. De Smaele E*, Di Marcotullio L*, Moretti M*, Pelloni M, Occhione MA, Infante P, Cucchi D, Greco A, Pietrosanti L, Todorovic J, Coni S, Canettieri G, Ferretti E, Bei R, Maroder M, Screpanti I, Gulino A. Identification and characterization of KCASH2 and KCASH3, two novel regulators of HDAC and Hedgehog activity in Medulloblastoma. Neoplasia 2011 Apr; 13(4):374-85. (*Co-Primo nome) IF 5.946
33. Correale S, Pirone L, Di marcotullio L, De Smaele E, Greco A, Mazza’ D., Moretti M, Alterio V, Vitagliano L, Di Gaetano S, Gulino A, Pedone EM. Molecular organization of the cullin 3 ligase adaptor KCTD11. Biochimie 2011 Apr;93(4):715-24. IF 3.022
34. Di Marcotullio L, Greco A, Mazzà D, Canettieri G, Pietrosanti L, Infante P, Coni S, Moretti M, De Smaele E, Ferretti E, Screpanti I, Gulino A. Numb activates the E3 ligase Itch to control Gli1 function through a novel degradation signal. Oncogene 2011 Jan 6;30(1):65-76. IF 6.373
35. De Smaele E, Fragomeli C, Ferretti E, Pelloni M, Po A, Canettieri G, Coni S, Di Marcotullio L, Greco A, Moretti M, Di Rocco C, Pazzaglia S, Maroder M, Screpanti I, Giannini G, Gulino A. An integrated approach identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. Neoplasia. 2008 Jan;10(1):89-98. IF 5.946
Book Chapters:
1. Moretti M., Di Francesco B., Nolfi M.D.V., Angrisani A., De Smaele E. (2021) Methods for Modulating the Pathway of NF-κB Using Short Hairpin RNA (ShRNA). In: Franzoso G., Zazzeroni F. (eds) NF-κB Transcription Factors. Methods in Molecular Biology, vol 2366. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1669-7_6 (Book Chapter).
2. Bennett J, Moretti M, Thotakura AK, Tornatore L, Franzoso G. The regulation of the JNK cascade and programmed cell death by NF-κB: Mechanisms and functions. Trends in Stem Cell Proliferation and Cancer Research, 2013 (Book Chapter).